Tianjin Chase Sun Pharmaceutical Co., Ltd.

Established in 1996, it was listed on the first batch of GEM in the country in 2009. It is a state-owned enterprise under the State Assets Administration Commission. The controlling shareholder Chengdu Xingcheng Investment Group Co., Ltd. is one of the world's top 500 companies, ranking 493rd. Mainly engaged in the production, operation and research and development of pharmaceuticals and medical devices. The main products include: xibijing injection, moxifloxacin hydrochloride injection (Anrotai), low molecular weight heparin calcium injection (Bopuqing), traditional Chinese medicine formula granules, medical devices, pharmaceutical excipients, etc. Corporate honors: It has won many honors such as a national key high-tech enterprise, a national technological innovation demonstration enterprise, the National Advanced Collective for Poverty Alleviation, the Tianjin Science and Technology Progress Award, and 17th place in the “2023 Top 100 Chinese Medicine Ranking”.